News Conference News AHA 2024 ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS Michael O'Riordan November 21, 2024
News Conference News AHA 2024 Lifestyle and Risk Factors Matter for AF Burden—Metformin May Not: TRIM-AF Shelley Wood November 18, 2024
News Conference News ESC 2024 Edoxaban Monotherapy Wins for AF and Stable Coronary Disease: EPIC-CAD Todd Neale September 01, 2024
News Conference News NY Valves 2024 Polymer Mitral Valve Shows Well Early, but Long-term Data Key Michael O'Riordan June 12, 2024
News Conference News AHA 2023 NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear L.A. McKeown November 12, 2023
News Conference News EAS 2023 With New LDL Goalposts in FH, Combo Therapy Must Start Early Michael O'Riordan May 29, 2023
News Conference News AHA 2022 Partial Oral Antibiotic Regimen for Endocarditis Effective in Real World Michael O'Riordan November 10, 2022
News Conference News AHA 2022 High-Sensitivity Troponin Testing on the Rise in the US but Still Limited Michael O'Riordan November 04, 2022
News Conference News ESC 2022 Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE Michael O'Riordan August 31, 2022
News Conference News AHA 2021 Pharmacist-Led Intervention Slashes LDL and BP in 10,000 Patients Michael O'Riordan November 13, 2021
News Conference News TCT 2021 Failed MitraClip Is Uncommon, but Bleak When It Happens Michael O'Riordan October 08, 2021
News Conference News AHA 2020 Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials Michael O'Riordan November 17, 2020
News Conference News ESC 2020 EVAPORATE: Icosapent Ethyl May Slow Atherosclerosis Progression Yael L. Maxwell September 02, 2020
News Conference News ESC 2019 New PURE Insights: CVD Deaths Dip in Rich Nations Amid Risk-Factor Surprises Michael O'Riordan September 04, 2019
News Conference News TCT 2018 More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses Michael O'Riordan September 24, 2018
News Conference News ACC 2017 Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe Todd Neale March 18, 2017
News Conference News TCT 2015 Discussion Highlights Merits, Limitations of Small Trials Yael L. Maxwell October 13, 2015